How Do DOACs Perform After TAVR in Patients with Atrial Fibrillation?

Edoxaban was noninferior to a vitamin K antagonist for preventing an adverse clinical event but carried a greater bleeding risk.

Patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR) traditionally receive vitamin K antagonists (VKAs) because of the long history of warfarin use in patients with valve replacements and the inferiority of direct-acting oral anticoagulants (DOACs) compared with warfarin in those with mechanical valves. In the industry-funded, multicenter, open-label ENVISAGE-TAVI AF trial (NCT02943785), researchers compared the safety and efficacy of the DOAC edoxaban and a VKA in this setting.

Among 1426 patients randomized to edoxaban or a VKA for prevalent (99%) or incident AF after successful TAVR, during a median follow-up of approximately 1.5 years, the groups had similar rates of the composite primary effica…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

How Do DOACs Perform After TAVR in Patients with Atrial Fibrillation?

Topics

Reviewing Author